Análise de custo-minimização entre o Infliximabe (IFX) e o Adalimumabe (ADA) no tratamento da doença de Crohn (DC)

Kotze, Paulo Gustavo; Albuquerque, Idblan Carvalho de; Moraes, Antônio Carlos; Vieira, Andrea; Souza, Fernando de.
Rev. bras. colo-proctol ; 29(2): 158-168, abr.-jun. 2009. graf, tab
Artículo en Portugués | LILACS | ID: lil-524765

Documentos relacionados

  1. Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies.
  2. [Early biological therapy for Crohn's disease: which patients and how to carry out].
  3. Biologic therapies for Crohn's disease: optimising the old and maximising the new.
  4. Top-down approach to biological therapy of Crohn's disease.
  5. Conventional and biological therapy for inflammatory bowel disease.
  6. Silane-Functionalized Carbon Dots and Their Polymerized Hybrids: From Optoelectronics to Biotherapy.
  7. Efficiency of Ustekinumab in Crohn's Disease with Severe Psoriasiform Rash Induced by Biotherapies in an Adolescent.
  8. How to avoid treating irritable bowel syndrome with biologic therapy for inflammatory bowel disease.
  9. 30 Years of Biotherapeutics Development-What Have We Learned?
  10. The promise and challenges of cell therapy for psoriasis.